PAVMPAVmed Inc.

PortIO data may enable faster 510(k) pathway instead of De Novo route.

PAVmed Inc (PAVM) reports a significantly reduced net loss, advances the VARIS commercial launch at Ohio State, and explores a faster 510(k) pathway for PortIO.

Moby summary of PAVmed Inc.'s Q2 2026 earnings call

Moby summary of PAVmed Inc.'s Q1 2026 earnings call

PAVmed Inc (PAVM) navigates a transformative quarter with capital restructuring and promising subsidiary developments, despite facing financial hurdles and increased operating expenses.

Lishan Aklog: Thank you, Matt, and good morning, everyone. On our last quarterly call, I described how over the past now 2 years, we've undertaken a series of very deliberate and systematic actions to effectively permanently fix PAVmed's legacy capital structure and ultimately strengthen its balance sheet and improve our ability to execute on our strategic plan.

PAVmed (PAVM) delivered earnings and revenue surprises of -69.57% and -78.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -40.00% and -10.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Microbot Medical (MBOT) delivered earnings and revenue surprises of +37.50% and -76.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?